Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Fallopian Tube Cancer

Interventions: Drug: temsirolimus

First Posted Date: 2007-02-01

Last Posted Date: 2019-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00429793

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Ovarian Sarcoma
Ovarian Stromal Cancer
Recurrent Endometrial Carcinoma
Recurrent Ovarian Epithelial Cancer
Recurrent Ovarian Germ Cell Tumor
Stage III Endometrial Carcinoma
Stage III Ovarian Epithelial Cancer
Stage III Ovarian Germ Cell Tumor
Stage IV Endometrial Carcinoma
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: temsirolimus

First Posted Date: 2006-12-07

Last Posted Date: 2014-06-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT00408655

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: lenalidomide
Drug: temsirolimus
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-11-10

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00398515

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

Phase 2

Completed

Conditions: Stage IIIC Skin Melanoma
Recurrent Melanoma
Stage IIIB Skin Melanoma
Stage IV Skin Melanoma

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2006-11-10

Last Posted Date: 2017-06-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00397982

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sorafenib Tosylate
Drug: Temsirolimus

First Posted Date: 2006-09-21

Last Posted Date: 2018-11-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 361

Registration Number: NCT00378703

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, United States

and more 554 locations

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Carcinoma
Stage IIIA Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Stage III Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2006-09-15

Last Posted Date: 2020-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00376688

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 1

Completed

Conditions: Stage IV Melanoma
Melanoma
Recurrent Melanoma
Stage III Melanoma

Interventions: Drug: sorafenib tosylate
Drug: temsirolimus

First Posted Date: 2006-07-06

Last Posted Date: 2014-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 69

Registration Number: NCT00349206

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 1

Completed

Conditions: Adult Gliosarcoma
Recurrent Adult Brain Tumor
Adult Giant Cell Glioblastoma
Adult Glioblastoma

Interventions: Drug: sorafenib tosylate
Drug: erlotinib hydrochloride
Drug: temsirolimus
Drug: tipifarnib

First Posted Date: 2006-06-12

Last Posted Date: 2018-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT00335764

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Glioblastoma

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Conventional Surgery
Drug: Sorafenib Tosylate
Drug: Temsirolimus

First Posted Date: 2006-05-25

Last Posted Date: 2018-10-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 115

Registration Number: NCT00329719

Locations: 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸
Illinois CancerCare-Macomb, Macomb, Illinois, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 186 locations

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Other: pharmacological study
Procedure: adjuvant therapy
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy
Drug: temsirolimus
Drug: temozolomide

First Posted Date: 2006-04-21

Last Posted Date: 2013-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00316849

Locations: 🇺🇸
Altru Cancer Center, Grand Forks, North Dakota, United States
🇺🇸
Medical Oncology and Hematology Associates, Des Moines, Iowa, United States
🇺🇸
Iowa Lutheran Hospital, Des Moines, Iowa, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy